<DOC>
<DOCNO>EP-0658082</DOCNO> 
<TEXT>
<INVENTION-TITLE>
COMBINATION OF GERMICIDAL AGENTS
</INVENTION-TITLE>
<CLASSIFICATIONS>A61Q1500	C07D23300	A61K31415	C07D23364	A61K3800	A01N4348	A61K864	A61K3800	A61K830	A01N6302	A61K844	A61K31415	A61Q502	A01N6302	A61Q502	A61K800	A61Q1500	A61K800	A61K849	A01N4350	</CLASSIFICATIONS>
<CLASSIFICATIONS-THIRD>A61Q	C07D	A61K	C07D	A61K	A01N	A61K	A61K	A61K	A01N	A61K	A61K	A61Q	A01N	A61Q	A61K	A61Q	A61K	A61K	A01N	</CLASSIFICATIONS-THIRD>
<CLASSIFICATIONS-FOURTH>A61Q15	C07D233	A61K31	C07D233	A61K38	A01N43	A61K8	A61K38	A61K8	A01N63	A61K8	A61K31	A61Q5	A01N63	A61Q5	A61K8	A61Q15	A61K8	A61K8	A01N43	</CLASSIFICATIONS-FOURTH>
<ABSTRACT>
Combinations of imidazol and/or one or more imidazol derivatives with general structural formula (I) in which the residues may be as follows: R1 = H, C(1 - 25) alkyl, R2 = H, C(1 - 25) alkyl, R3 = H, C(1 - 25) alkyl, R4 = H, C(1 - 25) alkyl, where R4 may also, and preferably when R1, R2 and R3 are a hydrogen atom, be the residues -CH2-CH2-NR5R6 and -CH2-CH(NR5R6)-COOR7, where R5 = H, C(1 - 25) alkyl, R6 = H, C(1 - 25) alkyl, R7 = H, C(1 - 25) alkyl, and of a substance active against micro-organisms or a mixture from the lantibiotics group.
</ABSTRACT>
<APPLICANTS>
<APPLICANT-NAME>
BEIERSDORF AG
</APPLICANT-NAME>
<APPLICANT-NAME>
BEIERSDORF AKTIENGESELLSCHAFT
</APPLICANT-NAME>
</APPLICANTS>
<INVENTORS>
<INVENTOR-NAME>
KLEIN WINFRIED
</INVENTOR-NAME>
<INVENTOR-NAME>
MATTHIES EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
SAUERMANN GERHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIDT-LEWERKUEHNE HARTMUT
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMUCKER ROBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
TRAUPE BERND
</INVENTOR-NAME>
<INVENTOR-NAME>
KLEIN, WINFRIED
</INVENTOR-NAME>
<INVENTOR-NAME>
MATTHIES, EVA
</INVENTOR-NAME>
<INVENTOR-NAME>
SAUERMANN, GERHARD
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMIDT-LEWERKUEHNE, HARTMUT
</INVENTOR-NAME>
<INVENTOR-NAME>
SCHMUCKER, ROBERT
</INVENTOR-NAME>
<INVENTOR-NAME>
TRAUPE, BERND
</INVENTOR-NAME>
</INVENTORS>
<CLAIMS>
Combinations of imidazole and/or one or more
derivatives of imidazole which have the following general

structural formula

wherein the radicals can have the following
meaning:


R
1
 = H or C
1 - 25
 - alkyl,
R
2
 = H or C
1 - 25
 - alkyl,
R
3
 = H or C
1 - 25
 - alkyl,
R
4
 = H or C
1 - 25
 - alkyl,
wherein R
4
 can also, and preferably if R
1
, R
2
 and
R
3
 are a hydrogen atom, be the radicals

-CH
2
-CH
2
-NR
5
R
6

and
-CH
2
-CH(NR
5
R
6
)-COOR
7
,

wherein

R
5
 = H or C
1 - 25
 - alkyl,
R
6
 = H or C
1 - 25
 - alkyl,
R
7
 = H or C
1 - 25
 - alkyl,

and a lantibiotic or a mixture of two or more
lantibiotics.
Combinations according to Claim 1, wherein the
lantibiotics are chosen from the group consisting of

nisin, epidermin, subtilin, cinramycin, duramycin,
ancovenin, Pep 5 and gallidermin.
Combinations according to Claim 1, wherein the
imidazole derivatives are chosen from the group consisting

of unsubstituted imidazole, histidine and histamine.
Combination according to Claim 1, characterized
by a content of 


0.01 - 99.99 % by weight
of an imidazole component
and
99.99 - 0.01 % by weight
of an individual substance
or a mixture from

the group of lantibiotics,

based on the total weight of the combination.
Formulations comprising combinations according to
Claim 1, wherein the lantibiotics are present in a

content of 0.1 - 10000 ppm, based on the total weight of

the formulations.
Formulations comprising combinations according to
Claim 1, wherein the lantibiotics are present in a

content of 0.1 - 750 ppm, based on the total weight of
the formulations.
Formulations comprising combinations according to
Claim 1, wherein the lantibiotics are present in a

content of 0.5 - 400 ppm, based on the total weight of
the formulations.
Formulations comprising combinations according to
Claim 1, wherein the imidazole derivative or derivatives

are present in a concentration of 0.01 - 5.00% by weight,
based on the total weight of the formulations.
Formulations comprising combinations according to
Claim 1, wherein the imidazole derivative or derivatives

are present in a concentration of 0.10 - 2.00% by weight,
based on the total weight of the formulations.
Formulations comprising combinations according to
Claim 1, wherein the imidazole derivative or derivatives

are present in a concentration of 0.4 - 0.6% by weight,
based on the total weight of the formulations.
Formulations according to one of Claims 1 - 10,
characterized in that they are in the form of deodorant

sprays, roll-ons, pump sprays, tinctures, intimate
cleansing compositions, shampoos, shower or bath formulations,

powders, powder sprays or deo sticks.
Use of one or more derivatives of imidazole which
have the following general structural formula 


wherein the radicals can have the following
meaning:


R
1
 = H or C
1 - 25
 - alkyl,
R
2
 = H or C
1 - 25
 - alkyl,
R
3
 = H or C
1 - 25
 - alkyl,
R
4
 = H or C
1 - 25
 - alkyl,
wherein R
4
 can also, and preferably if R
1
, R
2
 and
R
3
 are a hydrogen atom, be the radicals

-CH
2
-CH
2
-NR
5
R
6

and
-CH
2
-CH(NR
5
R
6
)-COOR
7
,

wherein

R
5
 = H or C
1 - 25
 - alkyl,
R
6
 = H or C
1 - 25
 - alkyl,
R
7
 = H or C
1 - 25
 - alkyl,

for stabilizing lantibiotics.
Use of combinations according to one of
Claims 1 - 3 for the preparation of a dermatological

formulation against acne.
</CLAIMS>
</TEXT>
</DOC>
